InflaRx's Vilobelimab Shows Mixed Results in Pyoderma Gangrenosum Trial
Event summary
- InflaRx presented Phase 3 trial data for vilobelimab in pyoderma gangrenosum at the 2026 AAD Annual Meeting, showing mixed efficacy results.
- The trial was terminated early due to futility, with 20.8% of vilobelimab patients achieving complete target ulcer closure vs. 16.7% on placebo.
- Vilobelimab demonstrated a 76.6% reduction in C5a levels compared to -13.5% with placebo, with a generally well-tolerated safety profile.
- InflaRx plans to discuss potential development paths for vilobelimab in PG with the FDA, likely in collaboration with a partner.
The big picture
InflaRx's vilobelimab trial results highlight the challenges of developing treatments for rare inflammatory skin diseases. While the data suggest some clinical activity, the early trial termination underscores the difficulty in achieving statistically significant endpoints. The company's focus on regulatory discussions and potential partnerships reflects the strategic shift toward collaborative development in niche dermatology indications.
What we're watching
- Regulatory Strategy
- Whether InflaRx can secure FDA guidance for vilobelimab in PG despite the trial's early termination.
- Partnership Dynamics
- The pace at which InflaRx identifies a development partner for vilobelimab in PG.
- Pipeline Prioritization
- How InflaRx balances resources between vilobelimab and its lead program, izicopan, for hidradenitis suppurativa.
Related topics